nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
ABO Antibody Titer and Risk of Antibody‐Mediated Rejection in ABO‐Incompatible Renal Transplantation
|
Tobian, A.A.R. |
|
|
10 |
5 |
p. 1247-1253 |
artikel |
2 |
An Ongoing Issue Concerning Facial Transplantation
|
Strong, C. |
|
|
10 |
5 |
p. 1115-1116 |
artikel |
3 |
Antibody‐Mediated Rejection: Emergence of Animal Models to Answer Clinical Questions
|
Baldwin III, William M. |
|
|
10 |
5 |
p. 1135-1142 |
artikel |
4 |
Authors’ Response: The Riskiest Job in Medicine: Transplant Surgeons and Organ Procurement Travel
|
Englesbe, Michael J. |
|
|
10 |
5 |
p. 1335 |
artikel |
5 |
Better the Devil You Know: Response to Professor Ponticelli and Colleagues
|
Hidalgo, L.G. |
|
|
10 |
5 |
p. 1333 |
artikel |
6 |
CCR2 Regulates Monocyte Recruitment As Well As CD4+ Th1 Allorecognition After Lung Transplantation
|
Gelman, A.E. |
|
|
10 |
5 |
p. 1189-1199 |
artikel |
7 |
Commemorating the 10th anniversary of the launch of the AJT project
|
Halloran, Philip F. |
|
|
10 |
5 |
p. 1111 |
artikel |
8 |
Differential Requirement of CD27 Costimulatory Signaling for Naïve Versus Alloantig(en‐Primed Effector/Memory CD8+ T Cells
|
Yamaura, K. |
|
|
10 |
5 |
p. 1210-1220 |
artikel |
9 |
Distinct Mechanism of Small‐for‐Size Fatty Liver Graft Injury—Wnt4 Signaling Activates Hepatic Stellate Cells
|
Cheng, Q. |
|
|
10 |
5 |
p. 1178-1188 |
artikel |
10 |
Donor Intervention and Organ Preservation: Where Is the Science and What Are the Obstacles?
|
Feng, S. |
|
|
10 |
5 |
p. 1155-1162 |
artikel |
11 |
Editorial Board Members and Staff, 2000–present
|
|
|
|
10 |
5 |
p. 1112 |
artikel |
12 |
Efficacy of Induction Therapy with ATG and Intravenous Immunoglobulins in Patients with Low‐Level Donor‐Specific HLA‐Antibodies
|
Bächler, K. |
|
|
10 |
5 |
p. 1254-1262 |
artikel |
13 |
Elective Surgical Patients as Living Organ Donors: A Clinical and Ethical Innovation
|
Testa, G. |
|
|
10 |
5 |
p. 1331 |
artikel |
14 |
Erratum
|
|
|
|
10 |
5 |
p. 1337 |
artikel |
15 |
Evolving Paradigms That Determine the Fate of an Allograft
|
Bromberg, J.S. |
|
|
10 |
5 |
p. 1143-1148 |
artikel |
16 |
Fulminant Wilson's Disease Requiring Liver Transplantation in One Monozygotic Twin Despite Identical Genetic Mutation
|
Kegley, K.M. |
|
|
10 |
5 |
p. 1325-1329 |
artikel |
17 |
Hair Analysis Versus Conventional Methods of Drug Testing in Substance Abusers Seeking Organ Transplantation
|
Haller, D.L. |
|
|
10 |
5 |
p. 1305-1311 |
artikel |
18 |
HBV and HIV Coinfection and Liver Transplant
|
Coffin, C.S. |
|
|
10 |
5 |
p. 1268-1275 |
artikel |
19 |
Hepatitis E Virus‐Induced Neurological Symptoms in a Kidney‐Transplant Patient with Chronic Hepatitis
|
Kamar, N. |
|
|
10 |
5 |
p. 1321-1324 |
artikel |
20 |
Histidine‐Tryptophan‐Ketoglutarate for Pancreas Allograft Preservation: The Indiana University Experience
|
Fridell, J.A. |
|
|
10 |
5 |
p. 1284-1289 |
artikel |
21 |
Histopathology and Immunophenotype of the Spleen During Acute Antibody‐Mediated Rejection
|
Kaplan, B. |
|
|
10 |
5 |
p. 1316-1320 |
artikel |
22 |
Humoral Antibodies in Organ Transplantation: Angels or Demons?
|
Ponticelli, Claudio |
|
|
10 |
5 |
p. 1332 |
artikel |
23 |
Kidneys for Sale: Who Disapproves, and Why?
|
Leider, S. |
|
|
10 |
5 |
p. 1221-1227 |
artikel |
24 |
Kidneys for Sale: Whose Attitudes Matter?
|
Segev, D.L. |
|
|
10 |
5 |
p. 1113-1114 |
artikel |
25 |
Living Donation, are There Limits?
|
Mortier, F. |
|
|
10 |
5 |
p. 1330 |
artikel |
26 |
Low-Dose Rituximab for Posttransplant Recurrent Membranous Nephropathy
|
Cravedi, P. |
|
|
10 |
5 |
p. 1336 |
artikel |
27 |
Matrix Metalloproteinase 2 in Reduced‐Size Liver Transplantation: Beyond the Matrix
|
Padrissa‐Altés, S. |
|
|
10 |
5 |
p. 1167-1177 |
artikel |
28 |
Melanoma in Solid Organ Transplant Recipients
|
Zwald, F.O. |
|
|
10 |
5 |
p. 1297-1304 |
artikel |
29 |
Molecular Markers and Targeted Therapy of Skin Rejection in Composite Tissue Allotransplantation
|
Hautz, T. |
|
|
10 |
5 |
p. 1200-1209 |
artikel |
30 |
Overview of Guidelines for Establishing a Face Transplant Program: A Work in Progress
|
Siemionow, M. |
|
|
10 |
5 |
p. 1290-1296 |
artikel |
31 |
Phenotypic Expression of Recurrent Disease After Liver Transplantation
|
O’Grady, J.G. |
|
|
10 |
5 |
p. 1149-1154 |
artikel |
32 |
Recent Progress and New Perspectives in Studying T Cell Responses to Allografts
|
Valujskikh, A. |
|
|
10 |
5 |
p. 1117-1125 |
artikel |
33 |
Retransplantation After BK Virus Nephropathy in Prior Kidney Transplant: An OPTN Database Analysis
|
Dharnidharka, V.R. |
|
|
10 |
5 |
p. 1312-1315 |
artikel |
34 |
T Cell‐mediated Rejection of Kidney Transplants: A Personal Viewpoint
|
Halloran, P.F. |
|
|
10 |
5 |
p. 1126-1134 |
artikel |
35 |
The AJT Report: News and issues that affect organ and tissue transplantation
|
Pondrom, Sue |
|
|
10 |
5 |
p. 1109-1110 |
artikel |
36 |
The Diagnostic Conundrum and Liver Transplantation Outcome for Combined Hepatocellular‐Cholangiocarcinoma
|
Panjala, C. |
|
|
10 |
5 |
p. 1263-1267 |
artikel |
37 |
The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High‐Risk Kidney Transplant Recipients
|
Humar, A. |
|
|
10 |
5 |
p. 1228-1237 |
artikel |
38 |
The Elephant in the Room: Failings of Current Clinical Endpoints in Kidney Transplantation
|
Schold, J.D. |
|
|
10 |
5 |
p. 1163-1166 |
artikel |
39 |
The Riskiest Job in Medicine: Transplant Surgeons and Organ Procurement Travel
|
Garcia, V.D. |
|
|
10 |
5 |
p. 1334 |
artikel |
40 |
Underutilization of Hepatitis C-Positive Kidneys for Hepatitis C-Positive Recipients
|
Kucirka, L.M. |
|
|
10 |
5 |
p. 1238-1246 |
artikel |
41 |
Vascular Stents in the Management of Portal Venous Complications in Living Donor Liver Transplantation
|
Cheng, Y.F. |
|
|
10 |
5 |
p. 1276-1283 |
artikel |